The chemical name 1-(2,4-Dihydroxyphenyl)-2-(4-methoxyphenyl)ethanone describes a molecule that is also known as **resveratrol**.
**Resveratrol** is a natural compound found in various plants, particularly grapes, berries, peanuts, and red wine. It has gained considerable attention in research due to its potential health benefits, which include:
* **Antioxidant properties:** Resveratrol can neutralize free radicals, which are unstable molecules that can damage cells and contribute to aging and disease.
* **Anti-inflammatory effects:** It can suppress inflammation, a process that plays a role in various chronic diseases like cancer, heart disease, and arthritis.
* **Cardioprotective effects:** Studies suggest that resveratrol might help lower blood pressure, improve cholesterol levels, and protect the heart from damage.
* **Neuroprotective effects:** Resveratrol may have neuroprotective properties, potentially reducing the risk of neurodegenerative diseases like Alzheimer's and Parkinson's.
* **Anti-cancer effects:** Research suggests that resveratrol could inhibit the growth and spread of cancer cells in some cases.
**Research on resveratrol is ongoing and focused on:**
* **Understanding its mechanisms of action:** Scientists are trying to understand how resveratrol exerts its beneficial effects at a molecular level.
* **Developing resveratrol-based therapies:** Researchers are exploring the potential of resveratrol for treating various diseases, including cancer, heart disease, and neurodegenerative disorders.
* **Evaluating its safety and efficacy:** Studies are being conducted to determine the optimal dosage, potential side effects, and overall safety of resveratrol for human consumption.
**It's important to note that while resveratrol shows promise in research, more studies are needed to confirm its effectiveness and safety in humans. It's not a replacement for a healthy lifestyle and conventional medical treatments.**
| ID Source | ID |
|---|---|
| PubMed CID | 259632 |
| CHEMBL ID | 241858 |
| CHEBI ID | 182312 |
| SCHEMBL ID | 2948430 |
| Synonym |
|---|
| mls000736891 , |
| nsc-89759 |
| EN300-37037 |
| 1-(2,4-dihydroxyphenyl)-2-(4-methoxyphenyl)ethan-1-one |
| CHEBI:182312 |
| BRD-K85385671-001-02-2 |
| acetophenone, 2',4'-dihydroxy-2-(p-methoxyphenyl)- |
| SDCCGMLS-0066960.P001 |
| SPECTRUM_000796 |
| 1-(2,4-dihydroxyphenyl)-2-(4-methoxyphenyl)ethanone |
| 487-49-0 |
| nsc89759 |
| BSPBIO_003273 |
| SPECTRUM5_000157 |
| BSPBIO_001797 |
| smr000528412 |
| NCGC00095540-01 |
| nsc 89759 |
| KBIO2_003844 |
| KBIO2_001276 |
| KBIO3_002774 |
| KBIO2_006412 |
| KBIOGR_002057 |
| KBIOSS_001276 |
| SPECTRUM3_001777 |
| SPECTRUM2_000808 |
| SPECTRUM4_001479 |
| SPBIO_000675 |
| SPECTRUM212097 |
| OPREA1_716474 |
| NCGC00095540-03 |
| NCGC00095540-02 |
| AKOS000275879 |
| ononetin |
| CHEMBL241858 , |
| bdbm50295962 |
| 2,4-dihydroxy-4''-methoxydeoxybenzoin |
| STK856460 |
| HMS2270L16 |
| unii-4s084z7ys4 |
| 4s084z7ys4 , |
| CCG-38393 |
| F0900-1857 |
| 2',4'-dihydroxy-2-(4-methoxyphenyl)acetophenone |
| 1-(2,4-dihydroxy-phenyl)-2-(4-methoxy-phenyl)-ethanone |
| XHBZOAYMBBUURD-UHFFFAOYSA-N |
| 2,4-dihydroxy-4'-methoxydeoxybenzoin |
| 1-(2,4-dihydroxyphenyl)-2-(4-methoxyphenyl)-ethanone |
| SCHEMBL2948430 |
| mfcd00020119 |
| DTXSID50197590 |
| SR-01000395029-3 |
| sr-01000395029 |
| SR-01000395029-1 |
| ethanone, 1-(2,4-dihydroxyphenyl)-2-(4-methoxyphenyl)- |
| .alpha.-(4-methoxyphenyl)-2,4-dihydroxyacetophenone |
| 2,4-dihydroxyphenyl 4'-methoxybenzyl ketone |
| 2,4-dihydroxyphenyl 4-methoxybenzyl ketone |
| D4816 |
| BCP33059 |
| O-135 |
| 1-(2,4-dihydroxyphenyl)-2-(4-methoxyphenyl)ethanone. |
| A871884 |
| HY-108451 |
| SY051013 |
| LS-05750 |
| CS-0028714 |
| Class | Description |
|---|---|
| stilbenoid | Any olefinic compound characterised by a 1,2-diphenylethylene backbone. |
| [compound class information is derived from Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res] | |
| Protein | Taxonomy | Measurement | Average (µ) | Min (ref.) | Avg (ref.) | Max (ref.) | Bioassay(s) |
|---|---|---|---|---|---|---|---|
| Chain A, MAJOR APURINIC/APYRIMIDINIC ENDONUCLEASE | Homo sapiens (human) | Potency | 12.5893 | 0.0032 | 45.4673 | 12,589.2998 | AID2517 |
| Luciferase | Photinus pyralis (common eastern firefly) | Potency | 21.3313 | 0.0072 | 15.7588 | 89.3584 | AID588342 |
| BRCA1 | Homo sapiens (human) | Potency | 15.8489 | 0.8913 | 7.7225 | 25.1189 | AID624202 |
| phosphopantetheinyl transferase | Bacillus subtilis | Potency | 44.6684 | 0.1413 | 37.9142 | 100.0000 | AID1490 |
| ATAD5 protein, partial | Homo sapiens (human) | Potency | 16.7889 | 0.0041 | 10.8903 | 31.5287 | AID504466; AID504467 |
| USP1 protein, partial | Homo sapiens (human) | Potency | 56.2341 | 0.0316 | 37.5844 | 354.8130 | AID504865 |
| TDP1 protein | Homo sapiens (human) | Potency | 18.2003 | 0.0008 | 11.3822 | 44.6684 | AID686978; AID686979 |
| aldehyde dehydrogenase 1 family, member A1 | Homo sapiens (human) | Potency | 19.9526 | 0.0112 | 12.4002 | 100.0000 | AID1030 |
| nonstructural protein 1 | Influenza A virus (A/WSN/1933(H1N1)) | Potency | 11.2202 | 0.2818 | 9.7212 | 35.4813 | AID2326 |
| serine-protein kinase ATM isoform a | Homo sapiens (human) | Potency | 44.6684 | 0.7079 | 25.1119 | 41.2351 | AID485349 |
| NPC intracellular cholesterol transporter 1 precursor | Homo sapiens (human) | Potency | 3.5481 | 0.0126 | 2.4518 | 25.0177 | AID485313 |
| 15-hydroxyprostaglandin dehydrogenase [NAD(+)] isoform 1 | Homo sapiens (human) | Potency | 25.1189 | 0.0018 | 15.6638 | 39.8107 | AID894 |
| ras-related protein Rab-9A | Homo sapiens (human) | Potency | 3.9811 | 0.0002 | 2.6215 | 31.4954 | AID485297 |
| nuclear receptor ROR-gamma isoform 1 | Mus musculus (house mouse) | Potency | 35.4813 | 0.0079 | 8.2332 | 1,122.0200 | AID2546; AID2551 |
| survival motor neuron protein isoform d | Homo sapiens (human) | Potency | 17.7828 | 0.1259 | 12.2344 | 35.4813 | AID1458 |
| cytochrome P450 3A4 isoform 1 | Homo sapiens (human) | Potency | 12.5893 | 0.0316 | 10.2792 | 39.8107 | AID884; AID885 |
| Gamma-aminobutyric acid receptor subunit pi | Rattus norvegicus (Norway rat) | Potency | 12.5893 | 1.0000 | 12.2248 | 31.6228 | AID885 |
| Gamma-aminobutyric acid receptor subunit beta-1 | Rattus norvegicus (Norway rat) | Potency | 12.5893 | 1.0000 | 12.2248 | 31.6228 | AID885 |
| Gamma-aminobutyric acid receptor subunit delta | Rattus norvegicus (Norway rat) | Potency | 12.5893 | 1.0000 | 12.2248 | 31.6228 | AID885 |
| Gamma-aminobutyric acid receptor subunit gamma-2 | Rattus norvegicus (Norway rat) | Potency | 12.5893 | 1.0000 | 12.2248 | 31.6228 | AID885 |
| Gamma-aminobutyric acid receptor subunit alpha-5 | Rattus norvegicus (Norway rat) | Potency | 12.5893 | 1.0000 | 12.2248 | 31.6228 | AID885 |
| Gamma-aminobutyric acid receptor subunit alpha-3 | Rattus norvegicus (Norway rat) | Potency | 12.5893 | 1.0000 | 12.2248 | 31.6228 | AID885 |
| Gamma-aminobutyric acid receptor subunit gamma-1 | Rattus norvegicus (Norway rat) | Potency | 12.5893 | 1.0000 | 12.2248 | 31.6228 | AID885 |
| Gamma-aminobutyric acid receptor subunit alpha-2 | Rattus norvegicus (Norway rat) | Potency | 12.5893 | 1.0000 | 12.2248 | 31.6228 | AID885 |
| Gamma-aminobutyric acid receptor subunit alpha-4 | Rattus norvegicus (Norway rat) | Potency | 12.5893 | 1.0000 | 12.2248 | 31.6228 | AID885 |
| Gamma-aminobutyric acid receptor subunit gamma-3 | Rattus norvegicus (Norway rat) | Potency | 12.5893 | 1.0000 | 12.2248 | 31.6228 | AID885 |
| Gamma-aminobutyric acid receptor subunit alpha-6 | Rattus norvegicus (Norway rat) | Potency | 12.5893 | 1.0000 | 12.2248 | 31.6228 | AID885 |
| Gamma-aminobutyric acid receptor subunit alpha-1 | Rattus norvegicus (Norway rat) | Potency | 12.5893 | 1.0000 | 12.2248 | 31.6228 | AID885 |
| Gamma-aminobutyric acid receptor subunit beta-3 | Rattus norvegicus (Norway rat) | Potency | 12.5893 | 1.0000 | 12.2248 | 31.6228 | AID885 |
| Gamma-aminobutyric acid receptor subunit beta-2 | Rattus norvegicus (Norway rat) | Potency | 12.5893 | 1.0000 | 12.2248 | 31.6228 | AID885 |
| TAR DNA-binding protein 43 | Homo sapiens (human) | Potency | 12.5893 | 1.7783 | 16.2081 | 35.4813 | AID652104 |
| GABA theta subunit | Rattus norvegicus (Norway rat) | Potency | 12.5893 | 1.0000 | 12.2248 | 31.6228 | AID885 |
| Gamma-aminobutyric acid receptor subunit epsilon | Rattus norvegicus (Norway rat) | Potency | 12.5893 | 1.0000 | 12.2248 | 31.6228 | AID885 |
| [prepared from compound, protein, and bioassay information from National Library of Medicine (NLM), extracted Dec-2023] | |||||||
| Protein | Taxonomy | Measurement | Average | Min (ref.) | Avg (ref.) | Max (ref.) | Bioassay(s) |
|---|---|---|---|---|---|---|---|
| Polyphenol oxidase 2 | Agaricus bisporus | IC50 (µMol) | 140.2333 | 0.0340 | 3.9871 | 10.0000 | AID427670; AID427671; AID427672 |
| [prepared from compound, protein, and bioassay information from National Library of Medicine (NLM), extracted Dec-2023] | |||||||
| Process | via Protein(s) | Taxonomy |
|---|---|---|
| RNA polymerase II cis-regulatory region sequence-specific DNA binding | TAR DNA-binding protein 43 | Homo sapiens (human) |
| DNA binding | TAR DNA-binding protein 43 | Homo sapiens (human) |
| double-stranded DNA binding | TAR DNA-binding protein 43 | Homo sapiens (human) |
| RNA binding | TAR DNA-binding protein 43 | Homo sapiens (human) |
| mRNA 3'-UTR binding | TAR DNA-binding protein 43 | Homo sapiens (human) |
| protein binding | TAR DNA-binding protein 43 | Homo sapiens (human) |
| lipid binding | TAR DNA-binding protein 43 | Homo sapiens (human) |
| identical protein binding | TAR DNA-binding protein 43 | Homo sapiens (human) |
| pre-mRNA intronic binding | TAR DNA-binding protein 43 | Homo sapiens (human) |
| molecular condensate scaffold activity | TAR DNA-binding protein 43 | Homo sapiens (human) |
| [Information is prepared from geneontology information from the June-17-2024 release] | ||
| Assay ID | Title | Year | Journal | Article |
|---|---|---|---|---|
| AID588501 | High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Lethal Factor Protease, MLPCN compound set | 2010 | Current protocols in cytometry, Oct, Volume: Chapter 13 | Microsphere-based flow cytometry protease assays for use in protease activity detection and high-throughput screening. |
| AID588501 | High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Lethal Factor Protease, MLPCN compound set | 2006 | Cytometry. Part A : the journal of the International Society for Analytical Cytology, May, Volume: 69, Issue:5 | Microsphere-based protease assays and screening application for lethal factor and factor Xa. |
| AID588501 | High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Lethal Factor Protease, MLPCN compound set | 2010 | Assay and drug development technologies, Feb, Volume: 8, Issue:1 | High-throughput multiplex flow cytometry screening for botulinum neurotoxin type a light chain protease inhibitors. |
| AID1745845 | Primary qHTS for Inhibitors of ATXN expression | |||
| AID504812 | Inverse Agonists of the Thyroid Stimulating Hormone Receptor: HTS campaign | 2010 | Endocrinology, Jul, Volume: 151, Issue:7 | A small molecule inverse agonist for the human thyroid-stimulating hormone receptor. |
| AID588497 | High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain F protease, MLPCN compound set | 2010 | Current protocols in cytometry, Oct, Volume: Chapter 13 | Microsphere-based flow cytometry protease assays for use in protease activity detection and high-throughput screening. |
| AID588497 | High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain F protease, MLPCN compound set | 2006 | Cytometry. Part A : the journal of the International Society for Analytical Cytology, May, Volume: 69, Issue:5 | Microsphere-based protease assays and screening application for lethal factor and factor Xa. |
| AID588497 | High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain F protease, MLPCN compound set | 2010 | Assay and drug development technologies, Feb, Volume: 8, Issue:1 | High-throughput multiplex flow cytometry screening for botulinum neurotoxin type a light chain protease inhibitors. |
| AID651635 | Viability Counterscreen for Primary qHTS for Inhibitors of ATXN expression | |||
| AID588499 | High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain A protease, MLPCN compound set | 2010 | Current protocols in cytometry, Oct, Volume: Chapter 13 | Microsphere-based flow cytometry protease assays for use in protease activity detection and high-throughput screening. |
| AID588499 | High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain A protease, MLPCN compound set | 2006 | Cytometry. Part A : the journal of the International Society for Analytical Cytology, May, Volume: 69, Issue:5 | Microsphere-based protease assays and screening application for lethal factor and factor Xa. |
| AID588499 | High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain A protease, MLPCN compound set | 2010 | Assay and drug development technologies, Feb, Volume: 8, Issue:1 | High-throughput multiplex flow cytometry screening for botulinum neurotoxin type a light chain protease inhibitors. |
| AID504810 | Antagonists of the Thyroid Stimulating Hormone Receptor: HTS campaign | 2010 | Endocrinology, Jul, Volume: 151, Issue:7 | A small molecule inverse agonist for the human thyroid-stimulating hormone receptor. |
| AID427665 | Antioxidant activity assessed as DPPH radical scavenging activity incubated at 40 degC in dark after 30 mins | 2009 | Bioorganic & medicinal chemistry, Jul-01, Volume: 17, Issue:13 | Potential antioxidants and tyrosinase inhibitors from synthetic polyphenolic deoxybenzoins. |
| AID977602 | Inhibition of sodium fluorescein uptake in OATP1B3-transfected CHO cells at an equimolar substrate-inhibitor concentration of 10 uM | 2013 | Molecular pharmacology, Jun, Volume: 83, Issue:6 | Structure-based identification of OATP1B1/3 inhibitors. |
| AID427666 | Antioxidant activity assessed as superoxide anion radical scavenging activity by spectrophotometry | 2009 | Bioorganic & medicinal chemistry, Jul-01, Volume: 17, Issue:13 | Potential antioxidants and tyrosinase inhibitors from synthetic polyphenolic deoxybenzoins. |
| AID977599 | Inhibition of sodium fluorescein uptake in OATP1B1-transfected CHO cells at an equimolar substrate-inhibitor concentration of 10 uM | 2013 | Molecular pharmacology, Jun, Volume: 83, Issue:6 | Structure-based identification of OATP1B1/3 inhibitors. |
| AID427670 | Inhibition of mushroom tyrosinase activity after 30 mins by spectrophotometry | 2009 | Bioorganic & medicinal chemistry, Jul-01, Volume: 17, Issue:13 | Potential antioxidants and tyrosinase inhibitors from synthetic polyphenolic deoxybenzoins. |
| AID427661 | Antioxidant activity assessed as inhibition of FeCl2-induced lipid peroxidation by thiocyanate method | 2009 | Bioorganic & medicinal chemistry, Jul-01, Volume: 17, Issue:13 | Potential antioxidants and tyrosinase inhibitors from synthetic polyphenolic deoxybenzoins. |
| AID715002 | Inhibition of mushroom tyrosinase using L-DOPA as substrate at 100 ug/ml after 10 mins | 2012 | Bioorganic & medicinal chemistry letters, Sep-01, Volume: 22, Issue:17 | Design, synthesis and molecular simulation studies of dihydrostilbene derivatives as potent tyrosinase inhibitors. |
| AID427663 | Antioxidant activity assessed as potassium ferric cyanide ion reducing power after 10 mins by Oyaizu method | 2009 | Bioorganic & medicinal chemistry, Jul-01, Volume: 17, Issue:13 | Potential antioxidants and tyrosinase inhibitors from synthetic polyphenolic deoxybenzoins. |
| AID427671 | Inhibition of mushroom tyrosinase activity after 90 mins by spectrophotometry | 2009 | Bioorganic & medicinal chemistry, Jul-01, Volume: 17, Issue:13 | Potential antioxidants and tyrosinase inhibitors from synthetic polyphenolic deoxybenzoins. |
| AID373071 | Inhibition of Helicobacter pylori ATCC 43504 urease assessed as ammonia production at 400 ug/mL by indophenol method | 2009 | European journal of medicinal chemistry, May, Volume: 44, Issue:5 | Amines and oximes derived from deoxybenzoins as Helicobacter pylori urease inhibitors. |
| AID427672 | Inhibition of mushroom tyrosinase activity after 150 mins by spectrophotometry | 2009 | Bioorganic & medicinal chemistry, Jul-01, Volume: 17, Issue:13 | Potential antioxidants and tyrosinase inhibitors from synthetic polyphenolic deoxybenzoins. |
| AID295603 | Inhibition of Helicobacter pylori ATCC 43504 urease at 400 ug/mL after 3 hrs pre-incubation | 2007 | Bioorganic & medicinal chemistry, Jun-01, Volume: 15, Issue:11 | Polyphenols based on isoflavones as inhibitors of Helicobacter pylori urease. |
| AID427662 | Antioxidant activity assessed as ferrous ion chelating effect after 10 mins | 2009 | Bioorganic & medicinal chemistry, Jul-01, Volume: 17, Issue:13 | Potential antioxidants and tyrosinase inhibitors from synthetic polyphenolic deoxybenzoins. |
| AID427664 | Antioxidant activity assessed as ABTS radical scavenging activity | 2009 | Bioorganic & medicinal chemistry, Jul-01, Volume: 17, Issue:13 | Potential antioxidants and tyrosinase inhibitors from synthetic polyphenolic deoxybenzoins. |
| AID1159550 | Human Phosphogluconate dehydrogenase (6PGD) Inhibitor Screening | 2015 | Nature cell biology, Nov, Volume: 17, Issue:11 | 6-Phosphogluconate dehydrogenase links oxidative PPP, lipogenesis and tumour growth by inhibiting LKB1-AMPK signalling. |
| AID1794808 | Fluorescence-based screening to identify small molecule inhibitors of Plasmodium falciparum apicoplast DNA polymerase (Pf-apPOL). | 2014 | Journal of biomolecular screening, Jul, Volume: 19, Issue:6 | A High-Throughput Assay to Identify Inhibitors of the Apicoplast DNA Polymerase from Plasmodium falciparum. |
| AID1794808 | Fluorescence-based screening to identify small molecule inhibitors of Plasmodium falciparum apicoplast DNA polymerase (Pf-apPOL). | |||
| AID1159607 | Screen for inhibitors of RMI FANCM (MM2) intereaction | 2016 | Journal of biomolecular screening, Jul, Volume: 21, Issue:6 | A High-Throughput Screening Strategy to Identify Protein-Protein Interaction Inhibitors That Block the Fanconi Anemia DNA Repair Pathway. |
| [information is prepared from bioassay data collected from National Library of Medicine (NLM), extracted Dec-2023] | ||||
| Timeframe | Studies, This Drug (%) | All Drugs % |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 4 (28.57) | 29.6817 |
| 2010's | 8 (57.14) | 24.3611 |
| 2020's | 2 (14.29) | 2.80 |
| [information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023] | ||
According to the monthly volume, diversity, and competition of internet searches for this compound, as well the volume and growth of publications, there is estimated to be weak demand-to-supply ratio for research on this compound.
| This Compound (11.72) All Compounds (24.57) |
| Publication Type | This drug (%) | All Drugs (%) |
|---|---|---|
| Trials | 0 (0.00%) | 5.53% |
| Reviews | 1 (7.14%) | 6.00% |
| Case Studies | 0 (0.00%) | 4.05% |
| Observational | 0 (0.00%) | 0.25% |
| Other | 13 (92.86%) | 84.16% |
| [information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023] | ||